Influence of the Clinical Status on Stress Reticulocytes, CD 36 and CD 49d of SSFA2 Homozygous Sickle Cell Patients Followed in Abidjan

Duni Sawadogo,1,2 Aïssata Tolo-Dilkébié,3 Mahawa Sangaré,1,2 Nelly Aguéhoudé,1 Hermance Kassi,4 and Toussaint Latte4

1 Department of Hematology, Faculty of Pharmacy, University Felix Houphouet Boigny, Cocody, BP 2308 Abidjan 08, Cote D’Ivoire
2 Unit of Hematology, Central Laboratory, Teaching Hospital of Yopougon, BP 632 Abidjan 21, Cote D’Ivoire
3 Clinic Hematology Service, Teaching Hospital of Yopougon, BP 632 Abidjan 21, Cote D’Ivoire
4 AIDS Biological Unit, Central Laboratory, Teaching Hospital of Yopougon, BP 632 Abidjan 21, Cote D’Ivoire

Correspondence should be addressed to Duni Sawadogo; dunisawadogo@yahoo.fr

Received 25 August 2013; Revised 12 January 2014; Accepted 12 January 2014; Published 27 February 2014

Copyright 2014 Duni Sawadogo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Objectives. Interactions between sickle cells involving CD 49d, CD36, and the vascular endothelium may initiate vasoocclusion leading to acute painful episodes and multiple organ failure. Materials and Methods. We selected 60 SS patients who had never been treated by hydroxyurea. We performed a total blood count. We identified with immunophenotyping by flow cytometry total reticulocytes their distribution according to the degree of maturity (mature, intermediate, very immature) and CD36+ and CD49d+ antigens. Stress reticulocytes corresponded to the sum of intermediate and immature cells. Results. Subjects in crisis had more total reticulocytes and very immature reticulocytes than subjects in stationary phase (𝑃<0.05). During the crisis, total CD36+ reticulocytes (214870±107584/µL versus 148878±115024/µL; 𝑃<0.05) and the very immature CD36+ reticulocytes (28.9±7.9% versus 23.0±6.4%; 𝑃<0.05) increased. The clinical status had no impact on CD49d+ reticulocytes. Conclusion. The rates of stress reticulocytes in general and those expressing CD49d and CD36 were very high. The clinical status had an influence on CD36+ reticulocytes. The expression of adhesion molecules is only one of the parameters involved in sickle cell disease crisis.

1. Introduction

Sickle cell anemia (SCA) is a pathology characterized by acute pain and various organ failures, related to frequent vasoocclusive episodes. The mechanism that leads to these vasoocclusive events is not yet clearly defined. Vasoocclusion may be due to an interaction between sickle cells and the vascular endothelium. The result is a longer transit time of sickle cells in the capillary system [1–3]. Some of the molecules involved in these interactions have been identified for example CD 47, basal cell adhesion molecule-1/Lutheran (B-CAM-1/Lu), intercellular cell adhesion molecule 4 (ICAM-4) [3–5]. In this paper, we focused on α5(49d) β1 (CD 29) integrin or very late activation antigen (VLA) 4 and CD 36 which are, exclusively present on stress reticulocytes [1–5].

Hydroxyurea (HU) is a cancer chemotherapy agent that decreases the frequency of SCA crises. HU may exert its therapeutic effect by generating nitric oxide (anti-inflammatory) and increasing the level of antisickling fetal hemoglobin (Hb F) [3, 5, 6]. Higher levels of Hb F result in clinically milder sickle cell disease [3, 6]. HU also led to a significant decrease in the expression of the CD 36, CD 49d, and CD 29 genes [7].

Lee et al. [8] and Trinh-Trang-Tan et al. [9] found that the presence or absence of CD 36 had no effect on the clinical manifestations of SCA. Browne and Hebbel [2] and Styles et al. [3] had a completely different point of view. In Côte d’Ivoire, the frequency of Hb S hovers around 14% with 2% of major forms [10]. HU is not part of the armamentarium used for the treatment of sickle cell patients. Patients
fluorescence intensity (MFI) was also measured. They found that the expression of CD 49d and CD 29 were virtually identical. On this basis, we only sought the expression of CD 49d [3].

Data were compared using Student’s t-test or Chi-Square test. A P value < 0.05 indicated a significant difference.

3. Results

60 SS patients (32 male and 28 female) were studied. The average age was 15.12 ± 10.57 (2–43 years). We separated patients according to clinical status: crisis or steady state (Table 1). Patients in crisis or in steady state had a similar distribution with regard to age, sex ratio, and the Hb fractions (Table 1). On the other hand, in terms of clinical history, subjects in crisis had had a longer length of hospital stay and a higher number of transfusions ($P < 0.05$) than subjects in steady state. Clinical status had an impact on most elements of the complete blood count (Table 1). Severe anemia and leukocytosis with neutrophilia were the highlights of the complete blood count (Table 1).

Subjects in crisis had statistically significantly more total reticulocytes (absolute and relative values) and very immature reticulocytes, HFR, than subjects in steady state (Table 2).

All patients (60/60) had expressed CD 49d on the reticulocytes. The distribution according to the degree of maturity was similar during the crisis or the steady state. Very immature cells predominated (Table 3).

80% (48/60) of patients expressed the CD 36. The mean fluorescence intensity (MFI) for the stress reticulocytes was 120 ± 10 whereas for the more mature reticulocytes MFI it was lower (35 ± 7). Stress reticulocytes were strongly stained. The relative and absolute rates of CD 36– reticulocytes were higher in crisis than in steady state (Table 4). Steady state was associated with an increase of CD 36+ intermediate maturity reticulocytes. Immature reticulocytes value was higher for the SS patients in crisis (Table 4).

4. Comments

Data on age and sex were similar to the other studies carried out in Abidjan which stressed that sickle cell patients were mostly teenagers or young male adults [10, 11].

Clinical history showed that patients who were recruited when they were in crisis received more transfusions and were hospitalized longer (Table 1). The frequency of painful crises requiring hospitalization and the length of hospital stay are clinical criteria used to assess the severity of SCA. Platt et al. [14] showed that the number of painful episodes in a year is a measure of the clinical severity of the disease and that it is associated with early death especially in patients over 20 years.

Indeed, SCA is associated with an abnormal inflammatory reaction which is even more important during crises [4, 10, 12]. Since the work of Sangare et al. [10] that has demonstrated the beneficial effect of nonsteroidal anti-inflammatory drugs, ketoprofen is used for treating seizures in Abidjan. It is associated with a vasodilator, pentoxifylline. This anti-inflammatory drug shortened significantly and without any
Table 1: Influence of clinical status on epidemiological, clinical, and biological parameters.

| Parameters                          | Painful crisis (n = 30) | Steady state (n = 30) | P  |
|------------------------------------|-------------------------|-----------------------|----|
| Age                                | 13.9 ± 9 (2–37)         | 16.4 ± 11.9 (2–43)    | 0.364 |
| Sex (M/F)                          | 1.14                    | 1.14                  | 0.795 |
| Number of crises/year              | 2.5 ± 1.01 (1–4)        | 2.3 ± 0.84 (1–4)      | 0.406 |
| Hospitalization days/year          | 1.4 ± 1.01 (0–6)        | 0.47 ± 0.63 (0–2)     | 0.0002 |
| Transfusions/year                  | 0.93 ± 0.52 (0–2)       | 0.43 ± 0.5 (0–1)      | 0.0004 |
| Hb S (%)                           | 86.8 ± 5.7 (76–95)      | 86.1 ± 4.5 (73.6–93.6)| 0.622 |
| Hb F (%)                           | 18.8 ± 5.1 (2.5–23.2)   | 11.5 ± 4.4 (3.9–23.6) | 0.595 |
| Hb A₂ (%)                          | 2.3 ± 1.01 (1–4)        | 2.4 ± 0.6 (1.5–4.2)   | 0.599 |
| Red blood cells/μL                 | 2 011 000 ± 698 000     | 2 593 000 ± 605 000   | 0.001 |
| Hemoglobin (g/dL)                  | 5.64 ± 1.81             | 6.98 ± 1.47           | 0.0024 |
| Hematocrit (%)                     | 17.83 ± 5.12            | 21.01 ± 4.03          | 0.01   |
| Mean cell volume (fL)              | 91.02 ± 10.94           | 82.42 ± 11.09         | 0.004  |
| MCH (pg)                           | 28.43 ± 3.15            | 27.32 ± 3.84          | 0.224  |
| MCHC (%)                           | 31.32 ± 2.22            | 33.15 ± 1.57          | 0.0005 |
| Leukocytes/μL                      | 23 778 ± 13 038         | 14 206 ± 11 515       | 0.004  |
| Neutrophils/μL                     | 13 046 ± 6 685          | 5 838 ± 3 013         | 10⁻⁶   |
| Platelets/μL                       | 323 133 ± 159 263       | 407 867 ± 173 572     | 0.53   |

m ± sd (min–max): mean ± standard deviation (minimum–maximum).
MCV: mean cell volume.
MHV: mean cell hemoglobin.
MCHC: mean cell hemoglobin concentration.
P: Student’s t-test.

Table 2: Distribution of reticulocytes according to their degree of maturity and to the clinical status.

| Parameters                          | Painful crisis (n = 30) | Steady state (n = 30) | P  |
|------------------------------------|-------------------------|-----------------------|----|
| Total reticulocytes (%)            | 15.5 ± 10               | 8.4 ± 4.9             | 0.003 |
| Total reticulocytes (μL)           | 283 678 ± 153 711       | 200 721 ± 10 708      | 0.002 |
| LFR                                | 51.5 ± 15.9             | 56.6 ± 7.5            | 0.3   |
| MFR                                | 37.9 ± 10               | 36.7 ± 5.4            | 0.18  |
| HFR (%)                            | 10.7 ± 9.9              | 6.7 ± 3.5             | 0.012 |
| IRF (%)                            | 48.6 ± 15.9             | 43.4 ± 7.5            | 0.3   |

m ± sd: mean ± standard deviation.
P: Chi-Square test.
LFR: low fluorescence reticulocytes or mature reticulocytes.
MFR: medium fluorescence reticulocytes or semimature reticulocytes.
HFR: high fluorescence reticulocytes or immature reticulocytes.
IRF: index reticulocytes fraction or stress reticulocytes (MFR + HFR).

Side effects the duration of sickle cell crisis and had an effect greater than that of a major opioid analgesic. Patients never had been treated by HU.

The clinical status, namely, the vasoocclusive crisis, had an impact on almost all parameters of the complete blood count except for the level of platelets (Table 1). The complete blood count has demonstrated abnormalities commonly described as severe anemia and leukocytosis [3, 8, 10, 15]. In the patients followed in the present study, a higher leukocyte count in the peripheral circulation and infections were shown. Infections related to the increase of white blood cells were often associated with the occurrence of vasoocclusive episodes. Sluggish flow, increased transit time, hypoxia, and therefore sickling may be due to the probable interaction between sickle cells and leukocytes in the microcirculation [5]. A new multistep model for vasoocclusion in sickle disease is thus proposed. In this model, sickle cells or secondary inflammatory stimuli induced endothelial activation, leading to recruitment of adherent leukocytes. These leukocytes interacted with red blood sickle cells, thus hampering microvascular blood flow. In the end, sickle cells are trapped leading to vasoocclusion, as shown by Frenette [16].

The values of total reticulocytes (Table 2) were close to the results of other authors such as Styles et al. [3], Lee et al. [8], and Maier-Redelsperger et al. [15], which highlighted a hyperreticulocytosis ranging from 259 000/μL.
Table 3: Profile of CD 49d+ reticulocytes according to their degree of maturity and the clinical status.

| Parameters               | CD 49d+ patients                  |          |          | P   |
|--------------------------|-----------------------------------|----------|----------|-----|
|                          | Painful crisis (n = 30)            | Steady state (n = 30) |       |     |
|                          | m ± sd                             | m ± sd   |          |     |
| Total reticulocytes (%)  | 44.1 ± 17.7                        | 40.9 ± 7.7 | 0.13   |     |
| Total reticulocytes (/μL)| 134 604 ± 108 223                  | 83 782 ± 54 222 | 0.06   |     |
| LFR                      | 9.9 ± 19.6                         | 5.8 ± 2.1 | 0.91   |     |
| MFR                      | 26.4 ± 8.5                         | 28.4 ± 6.5 | 0.8    |     |
| HFR (%)                  | 63.7 ± 18.1                        | 65.8 ± 7.6 | 0.19   |     |
| IRF (%)                  | 90.1 ± 19.6                        | 94.2 ± 2.1 | 0.65   |     |

m ± sd: mean ± standard deviation.
P: Chi-Square test.
LFR: low fluorescence reticulocytes or mature reticulocytes.
MFR: medium fluorescence reticulocytes or semi-mature reticulocytes.
HFR: high fluorescence reticulocytes or immature reticulocytes.
IRF: index reticulocytes fraction or stress reticulocytes (MFR + HFR).

Table 4: Distribution of CD 36+ reticulocytes according to their degree of maturity and the clinical status.

| Parameters               | CD 36+ patients                  |          |          | P     |
|--------------------------|-----------------------------------|----------|----------|-------|
|                          | Painful crisis (n = 23)            | Steady state (n = 25) |       |       |
|                          | m ± sd                             | m ± sd   |          |       |
| Total reticulocytes (%)  | 53.4 ± 14.3                        | 46.1 ± 11.4 | 0.006  | 10^{-5}|
| Total reticulocytes (/μL)| 214 870 ± 107 584                  | 144 878 ± 115 024 |       |       |
| LFR                      | 9.2 ± 7.4                          | 8.9 ± 6.4 | 0.32   |       |
| MFR                      | 61.0 ± 8.9                         | 68.1 ± 6.2 | 0.001  |       |
| HFR (%)                  | 28.9 ± 7.9                         | 23 ± 6.4  | 0.002  |       |
| IRF (%)                  | 90.1 ± 7.4                         | 91.2 ± 6.4 | 0.3    |       |

m ± sd: mean ± standard deviation.
P: Chi-Square test.
LFR: low fluorescence reticulocytes or mature reticulocytes.
MFR: medium fluorescence reticulocytes or semi-mature reticulocytes.
HFR: high fluorescence reticulocytes or immature reticulocytes.
IRF: index reticulocytes fraction or stress reticulocytes (MFR + HFR).

We only sought the expression of CD 49d which was positive for all patients (Table 2). The percentage of reticulocytes expressing CD 49d was 44.1 ± 17.7% for the painful crisis and 40.9 ± 7.7% for the steady state (Table 3). The difference was not significant (P = 0.37). Styles et al. [3] also found that the crisis or stationary phase did not influence the relative value of CD 49d+ reticulocytes. However, our results were higher than those of Styles et al. [3] and Lee et al. [8]. Styles et al. [3] had found that the percentage of reticulocytes expressing CD 49d was 29.0 ± 5.9%, that is, 129 000 ± 39 000/μL. Lee et al. [8] showed that 22 ± 2% reticulocytes carried CD 49d. These high rates could be explained by the fact that the subjects we selected were much more anemic.

For CD 36+ subjects, the level of total reticulocytes was 53.4 ± 14.3% for subjects in crisis and 46.1 ± 11.4% for subjects in steady state (Table 4). These results differed from those of Lee et al. [8] who only found 24% ± 8.1% CD 36+ reticulocytes. They were close to those of Styles et al. [3] with 55.3 ± 6.4% CD 36+ reticulocytes before HU treatment. Browne and Hebbel [2] obtained 39.8 ± 21.9% for the total...
reticulocytes of CD 36+ patients. This value was lower than the results of Lee [8] but higher than the percentage given by Styles et al. [3].

We investigated SCA patients who never received HU. We compared the results with authors [3, 8] who had worked on SS patients treated by HU. It is well documented that HU decreases CD 49d and CD 36 expression even after months [3, 8]. In fact, Lee et al. [8] collected the samples before the introduction of HU treatment. Styles et al. [3] followed the SCA patients from the onset of therapy with HU.

According to Styles et al. [3], we found that CD 36 expression on reticulocytes was higher than that of CD 49d. Nevertheless, these authors emphasized that adhesion mediated by VLA-4 or $\alpha_4\beta_1$ (CD 29) integrin would be more tenacious than that involving the CD 36 [3].

The contribution of CD 36 has been called into question with the finding that sickle cell patients who have a CD 36 deficiency of reticulocytes and mature red blood cells can have a normal clinical course [8, 9]. Trinh-Trang-Tan et al. [9] showed that there is dissociation between adhesiveness and adhesion molecules. It is therefore conceivable that CD 36, although in reduced amounts, might be activated by abnormal constitutive phosphorylation [9].

Blood flow is compromised in sickle microcirculation. Under low flow, sickle cell adherence to endothelium increased with contact time in the absence of endothelial activation or adhesive protein addition. Contact time between sickle cells and endothelium seemed a more important determinant of adherence than high-affinity receptor-ligand interactions [18].

The signalization cascade leading to receptor activation rather than the expression level only of adhesion molecules should also play an important role in the adhesion of sickle cells to the blood vessels [4].

5. Conclusion

In SCA, the clinical status—crisis or steady state—had an impact on the clinical history, namely, the number of hospital days and the number of transfusions. Anemia, leukocytosis, and total and immature reticulocytes were higher in patients in crisis than those in steady state. There was no difference between subjects in crisis and those in steady state for CD 49d+ reticulocytes. Concerning the CD 36+ subjects, the crisis had resulted in an increase in total reticulocytes and very immature reticulocytes.

SCA is the result of complex mechanism involving adhesion molecules such as CD 49d and CD 36. There is a correlation between the adhesion systems and the stress reticulocytes. However these facts are not sufficient to predict the occurrence and severity of sickle cell crisis.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] R. P. Hebbel, M. A. B. Boogaerts, J. W. Eaton, and M. H. Steinberg, “Erythrocyte adherence to endothelium in sickle-cell anaemia. A possible determinant of disease severity,” The New England Journal of Medicine, vol. 302, no. 18, pp. 992–995, 1980.
[2] P. V. Browne and R. P. Hebbel, “CD36-positive stress reticulocytosis in sickle cell anaemia,” Journal of Laboratory and Clinical Medicine, vol. 127, no. 4, pp. 340–347, 1996.
[3] L. A. Styles, B. Lubin, E. Vichinsky et al., “Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea,” Blood, vol. 89, no. 7, pp. 2554–2559, 1997.
[4] J.-P. Cartron and J. Elion, “Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea,” Transfus Clinique et Biologique, vol. 15, no. 1-2, pp. 39–50, 2008.
[5] D. K. Kau, E. Finnegan, and G. A. Barabino, “Sickle red cell-endothelium interactions,” Microcirculation, vol. 16, no. 1, pp. 97–111, 2009.
[6] S. Charache, M. L. Terrin, R. D. Moore et al., “Effect of hydroxyurea on the frequency of painful crises in Sickle cell anemia,” The New England Journal of Medicine, vol. 332, no. 20, pp. 1317–1322, 1995.
[7] S. Gambero, A. A. Canalli, F. Traina et al., “Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties,” European Journal of Haematology, vol. 78, no. 2, pp. 144–151, 2007.
[8] K. Lee, P. Gane, F. Roudot-Thoraval et al., “The nonexpression of CD36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia,” Blood, vol. 98, no. 4, pp. 966–971, 2001.
[9] M.-M. Trinh-Trang-Tan, C. Vilela-Lamego, J. Picot, M.-P. Wattier, and J.-P. Cartron, “Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium,” Haematologica, vol. 95, no. 5, pp. 730–737, 2010.
[10] A. Sangare, K. G. Koffi, O. Allangba et al., “Etude comparative du Ketoprofène et de la Buprenorphine dans le traitement des crises dououreuses drepanocytaires,” Medecine d’Afrique Noire, vol. 44, pp. 138–143, 1998.
[11] A. Tolo-Diebkile, K. G. Koffi, D. C. Nanho et al., “Drepanocytose homozygote chez l’adulte ivorien de plus de 21 ans,” Cahiers d’Études et de Recherches Francophones/Santé, vol. 20, pp. 63–67, 2010.
[12] A. A. Solovey, A. N. Solovey, J. Harkness, and R. P. Hebbel, “Modulation of endothelial cell activation in sickle cell disease: a pilot study,” Blood, vol. 97, no. 7, pp. 1937–1941, 2001.
[13] B. H. Davis, M. DiCorato, N. C. Bigelow, and M. H. Langweiler, “Proposal for standardization of flow cytometric reticulocyte maturity index (RMI) measurements,” Cytometry, vol. 14, no. 3, pp. 318–326, 1993.
[14] O. S. Platt, B. D. Thorington, D. J. Brambilla et al., “Pain in sickle cell disease—rates and risk factors,” The New England Journal of Medicine, vol. 325, no. 1, pp. 11–16, 1991.
[15] M. Maier-Redelsperger, A. Flahaut, M. G. Neonato, R. Girot, and D. Labie, “Automated analysis of mature red blood cells and reticulocytes in SS and SC disease,” Blood Cells, Molecules, and Diseases, vol. 33, no. 1, pp. 15–24, 2004.
[16] P. S. Frenette, “Sickle cell vaso-occlusion: multistep and multicellular paradigm,” Current Opinion in Hematology, vol. 9, no. 2, pp. 101–106, 2002.
[17] J. L. Wautier and M. P. Wautier, “Molecular basis of erythrocyte adhesion to endothelial cells in diseases,” Clinical Hemorheology and Microcirculation, vol. 53, pp. 11–21, 2013.

[18] R. A. O. Montes, J. R. Eckman, L. L. Hsu, and T. M. Wick, “Sickle erythrocyte adherence to endothelium at low shear: role of shear stress in propagation of vaso-occlusion,” American Journal of Hematology, vol. 70, no. 3, pp. 216–227, 2002.